This article aggregates 40+ questions patients commonly ask about MDMA-assisted therapy in Canada. For deeper coverage of any topic, follow the cross-links to the relevant cluster articles.
Compliance reminders: MDMA is Schedule I under the CDSA with no Health Canada approved indication. Clinical access is via the Special Access Program (SAP) only since the January 5, 2022 amendment. Recreational possession is illegal. The August 2024 FDA Complete Response Letter on Lykos's MDMA-AT for PTSD application has not changed Canadian SAP-pathway operations.
Quick navigation:
The basics — what MDMA-AT is and how it works {#the-basics}
1. What is MDMA-assisted therapy? MDMA-assisted therapy is a structured clinical model that pairs three high-dose MDMA sessions (typically 80 mg with optional 40 mg booster) over ~12 weeks with structured preparation and integration psychotherapy. Each dosing session is 6–8 hours in a clinical setting with two trained therapists. See What Is MDMA-Assisted Therapy?.
2. How does MDMA work? MDMA acts on the serotonin transporter to release serotonin, plus releases norepinephrine and dopamine, plus produces significant oxytocin release. The therapeutic state involves emotional warmth, reduced amygdala reactivity to threat cues, oxytocin-mediated relational opening, and reduced fear of vulnerability.
3. Is MDMA a "classic psychedelic"? No. MDMA acts primarily through serotonin release and oxytocin, not 5-HT2A partial agonism. The experiential profile is emotional warmth and conversational engagement rather than the perceptual disturbance and ego dissolution of classic psychedelics like psilocybin or LSD.
4. How is this different from "ecstasy"? MDMA is the pure pharmaceutical compound (3,4-methylenedioxymethamphetamine) at known concentration. Ecstasy or molly is street-market product that may contain MDMA but is frequently adulterated with methamphetamine, caffeine, novel psychoactive substances. Clinical MDMA-AT uses pharmaceutical-grade MDMA only.
5. Why are two therapists usually present? Most published trial protocols (Mitchell 2021/2023, Mithoefer 2018) use two trained therapists during dosing for continuity over the 6–8 hour session, patient–therapist match, safety redundancy, and active relational engagement during the therapeutic window.
Access and the SAP pathway {#access}
6. Is MDMA-assisted therapy legal in Canada? Yes — when accessed through Health Canada's Special Access Program (SAP). The legal pathway has been operational since the January 5, 2022 SAP amendment. Recreational possession remains illegal. See Is MDMA Therapy Legal in Canada?.
7. How does the SAP pathway work? A licensed physician or nurse practitioner submits a case-specific SAP request on behalf of an individual patient with a serious or life-threatening condition where conventional treatments have failed. Patients cannot apply directly. See How to Access MDMA-Assisted Therapy in Canada.
8. Can I apply for SAP myself as a patient? No. SAP applications are physician- or nurse-practitioner-initiated. You need a willing prescriber.
9. How do I find a willing prescriber? TheraPsil maintains a directory of trained Canadian clinicians and offers free patient consultations. MAPS Canada supports Canadian MDMA-AT advocacy. Numinus, Roots to Thrive, Quebec collective providers, and others have SAP-pathway experience.
10. How long does SAP review take? Historically 1–4 weeks; lengthening through 2025 per PsyCan reporting. Plan for 2–8 weeks or longer in 2026.
11. What's the SAP approval rate for MDMA? Historical SAP approval rates ran around 78% per industry reporting through 2024. Cumulative MDMA approvals reached ~41 by February 2024 (versus ~176 psilocybin). PsyCan reported sharp decline through 2025.
12. Where does the drug come from? Pharmaceutical-grade MDMA from Lykos Therapeutics clinical-trial supply or imported pharmaceutical MDMA through specific Health Canada authorization. Supply chain is more constrained than psilocybin's (no Filament-equivalent at scale).
13. Can a nurse practitioner apply for SAP? Yes. The January 2022 amendment authorized both physicians and nurse practitioners to submit SAP requests for MDMA and psilocybin.
Evidence — PTSD focus {#evidence}
14. What's the strongest evidence for MDMA-AT? PTSD specifically. Mitchell 2021 MAPP1 (Nat Med, N=90, d≈0.91) and Mitchell 2023 MAPP2 (Nat Med, N=104, d≈1.0) Phase 3 trials. The largest published psychedelic-assisted therapy RCT base for any condition. Mithoefer 2018 Lancet Psychiatry Phase 2 specifically in military veterans, firefighters, police.
15. Is MDMA-AT good for depression? Limited evidence. The published literature is heavily PTSD-focused. Some patients with comorbid TRD + PTSD may have depression respond alongside PTSD work, but MDMA-AT is not established for primary depression. Ketamine has substantially stronger TRD evidence.
16. Is MDMA-AT good for anxiety? Limited primary-anxiety evidence. Danforth 2018 demonstrated efficacy specifically in autistic-adult social anxiety, but this is a narrow indication. For primary GAD or SAD, MDMA-AT does not have established evidence; ketamine has more developed primary-anxiety evidence.
17. What about couples therapy with PTSD? Monson 2020 ARROW evidence supports cognitive-behavioural conjoint therapy combined with MDMA-AT for couples where one partner has PTSD. Emerging Canadian SAP-pathway use case.
18. Is MDMA-AT good for eating disorders? Emerging research; not yet a common Canadian SAP indication.
19. What conditions does Health Canada SAP authorize MDMA for? Overwhelmingly PTSD. Other indications (autistic-adult social anxiety, couples therapy with PTSD, eating disorders) are uncommon.
20. Why isn't MDMA-AT good for end-of-life distress like psilocybin? Different mechanisms target different therapeutic states. Psilocybin's mystical-type experience and meaning-making properties target existential distress directly. MDMA's emotional warmth and trauma-processing properties target PTSD specifically. Different tools for different jobs.
Cost and insurance {#cost}
21. How much does MDMA-AT cost in Canada? Typically CAD $7,500–$15,000 per program out-of-pocket — the highest of the three psychedelic-assisted therapy modalities. See MDMA-Assisted Therapy Cost in Canada.
22. Why is it more expensive than psilocybin or ketamine? Three dosing sessions (vs 1–2 psilocybin or 4–8 shorter ketamine sessions); more extensive integration phase (9 sessions across program); no Filament-equivalent free drug supply.
23. Does insurance cover MDMA-AT? Generally limited. Drug essentially never covered. Therapy fees may be partially covered as standard psychotherapy. VAC considers MDMA-AT case-by-case for service-related PTSD where SAP-approved — most accessible Canadian coverage pathway.
24. Does Quebec RAMQ cover MDMA-AT? No. The December 2022 Farzin/Stephan RAMQ precedent was psilocybin-specific and has not extended to MDMA.
25. Does Alberta Blue Cross PAT cover MDMA-AT? The March 2024 Alberta Blue Cross PAT coverage launched covering ketamine-assisted therapy. MDMA was framed as future potential once formally legalized. Confirm current scope.
26. Does WSIB Ontario or WCB Alberta cover MDMA-AT? Ketamine has formal coverage pathways with both. MDMA is not on formularies at this time. Possible case-by-case review for compensable PTSD.
The session experience {#session}
27. How long does a session last? 6–8 hours total in clinic. Three sessions across ~12 weeks plus preparation and integration. See What to Expect at an MDMA-Assisted Therapy Session.
28. What does the dosing experience feel like? Emotional warmth, increased connection, reduced fear of vulnerability, conversational availability, increased empathy. Not classic psychedelic visuals or ego dissolution. Patients typically remain able to engage in active trauma-focused therapeutic work during the 6–8 hour session.
29. Will I be able to talk during the experience? Yes — and most patients do. The "extended therapeutic window" allows active trauma-focused therapeutic exchange during the peak.
30. Will I have visions or hallucinations? Generally no. MDMA produces emotional and relational effects rather than the perceptual distortions of classic psychedelics.
31. Can I drive home afterward? No. 24-hour no-driving rule. Some Lykos Phase 3 protocols included overnight stays at clinic after the first dose.
32. How many sessions are in a program? Three dosing sessions over ~12 weeks; plus 3 preparation sessions before the first dose; plus 9 integration sessions (3 after each dosing day). ~24 sessions across the full program.
Safety and side effects {#safety}
33. Is MDMA-AT safe? At therapeutic supervised doses with appropriate pre-treatment screening, the published evidence supports acceptable safety. Mitchell 2021/2023 and Mithoefer 2018 12-month follow-up demonstrated acceptable safety profiles. See MDMA-Assisted Therapy Side Effects and Safety.
34. What are the most common side effects? Elevated heart rate and blood pressure, body temperature increase, jaw clenching, mild nausea early, post-session fatigue lasting 1–7 days, "midweek blues" 2–4 days post-dose. Most resolve within a week.
35. What's the most important contraindication? Concurrent MAOIs — absolute contraindication due to serotonin syndrome and hypertensive crisis risk.
36. Do I have to taper my SSRI? Most clinical protocols taper SSRIs/SNRIs before MDMA dosing. SSRIs attenuate MDMA's serotonergic effect through receptor adaptation; tapering is also a precaution against serotonin syndrome. Specific approach is individualized with the prescribing physician.
37. What about lithium, tramadol, stimulants? Lithium is reviewed case-by-case (not as established a contraindication as with classic psychedelics). Tramadol carries serotonin syndrome risk and is flagged. ADHD stimulants are typically held on dosing day.
38. What about the August 2024 FDA decision? The FDA Complete Response Letter on Lykos's MDMA-AT for PTSD application cited concerns about trial design (blinding integrity given MDMA's distinctive subjective effects) and allegations of clinical-site misconduct at certain MAPP1 sites. These are concerns about regulatory standards and trial conduct, not fundamental safety questions about MDMA at therapeutic supervised doses. Canadian SAP-pathway access continues independently.
39. Will MDMA-AT damage my brain? Recreational chronic high-dose MDMA use has a separate literature with concerns about serotonergic neurotoxicity. At therapeutic supervised three-session protocols with pharmaceutical-grade dosing, this has not emerged as a clinical concern in published trials.
Veterans and first responders {#veterans}
40. Does VAC cover MDMA-AT for veterans? Veterans Affairs Canada considers MDMA-AT case-by-case for service-related PTSD where SAP-approved. The most accessible Canadian coverage pathway. See MDMA-Assisted Therapy for Veterans.
41. What's the strongest evidence for service-connected populations? Mithoefer 2018 Lancet Psychiatry Phase 2 specifically in military veterans, firefighters, and police officers — sustained 12-month benefit. Mitchell 2021/2023 Phase 3 confirmed at scale.
42. What about WSIB Ontario / WCB Alberta first responders? Provincial presumptive PTSD legislation (Ontario Bill 163, expanded October 2024; Alberta Bill 27) accelerates eligibility for the underlying PTSD diagnosis. MDMA-AT case-by-case review applies for compensable PTSD; no formal MDMA listing at this time.
43. Can I do MDMA-AT through CNESST in Quebec? CNESST reviews psychedelic-medicine claims case-by-case. Specific MDMA-AT framework is less established than ketamine. Verify with CNESST directly.
Quebec specifics {#quebec}
44. Does Quebec RAMQ cover MDMA-AT? No. The December 2022 Farzin/Stephan RAMQ precedent was psilocybin-specific and has not extended to MDMA. See MDMA-Assisted Therapy in Quebec.
45. Does Bill 21 affect MDMA-AT in Quebec? Yes. The psychotherapy component of MDMA-AT must be delivered by a physician, psychologist, or OPQ psychotherapy permit holder. Unregulated coaches or counsellors cannot deliver the psychotherapy component in Quebec.
46. Where can I access MDMA-AT in Quebec? SAP-authorized clinicians with PTSD experience; Quebec collective via Drs. Farzin/Stephan or McGill colleagues; Neurotherapy Montreal; ATMA CENA's Montreal member clinic Clinic Dr. Bita; other Quebec psychiatrists with SAP-pathway experience.
Comparing to psilocybin and ketamine {#vs-others}
47. Which is better for PTSD: MDMA-AT or ketamine therapy? MDMA-AT has substantially stronger PTSD-specific RCT evidence (d≈0.91-1.0 vs ketamine pooled g≈0.20). Ketamine has broader Canadian access, established coverage, and lower cost. The realistic decision depends on access, coverage, and clinical fit. See MDMA vs Ketamine for PTSD.
48. How does MDMA-AT compare to psilocybin therapy? Different mechanisms (serotonin/NE/oxytocin vs 5-HT2A), different experiential profiles (emotional warmth vs classic psychedelic), different number of sessions (3 vs 1–2), different primary indications (PTSD vs end-of-life/TRD/AUD), different cost ($7,500–$15,000 vs $2,500–$6,500). Both SAP-only.
49. Can I do both MDMA-AT and ketamine therapy? Yes — sequenced at different times. Common patterns: ketamine for acute crisis stabilization or comorbid TRD; MDMA-AT later for trauma processing in a more stable phase. ATMA CENA's intake discusses sequencing where appropriate.
50. What if I have comorbid PTSD plus depression plus chronic pain? Common service-connected profile. Ketamine has stronger evidence for depression (CANMAT 2021 third-line) and chronic pain (ASRA 2018). MDMA-AT has stronger PTSD evidence. Sequencing across modalities or coordinated care across substances may be appropriate.
How ATMA CENA fits {#provider}
51. Does ATMA CENA directly administer MDMA? The medical SAP application is initiated by the patient's prescribing physician — not ATMA CENA directly. ATMA CENA supports preparation and integration through the three-phase psychedelic-assisted therapy model in coordination with the prescribing physician.
52. What's the coordinated care model? ATMA CENA's coordinated care framework lets your existing therapist remain the primary therapeutic relationship while ATMA CENA's clinical infrastructure provides the dosing-specific frame. Particularly relevant for trauma-focused work where existing therapeutic alliance often runs deep.
53. Can my existing therapist work with me through ATMA CENA? Yes — through coordinated care. In Quebec, your therapist must meet Bill 21 requirements (physician, psychologist, or OPQ permit holder). In other provinces, regulated psychotherapists, psychologists, and clinical counsellors generally fit.
54. Does ATMA CENA have MDMA-AT-trained therapists? ATMA CENA's training program prepares clinicians for psychedelic-assisted therapy work. Specific MDMA-AT-trained scope at ATMA CENA should be confirmed at intake.
55. Where are ATMA CENA's clinics? Corporate clinics in Edmonton and Calgary; member clinics across multiple provinces including Montreal (Clinic Dr. Bita). Confirm specific MDMA-AT pathway scope at intake.
What to do next {#next-steps}
56. What's the first step?
57. What if I don't have a prescribing physician? TheraPsil maintains a directory of trained Canadian clinicians. MAPS Canada supports Canadian MDMA-AT advocacy. Numinus, Roots to Thrive, Quebec collective providers, and others have SAP-pathway experience. The ATMA CENA intake call can orient you to appropriate Canadian resources.
58. What if I'm not a candidate for MDMA-AT? Many patients pursuing psychedelic-assisted therapy for PTSD are better served by ketamine — broader Canadian access, established VAC coverage, lower cost, faster acute response. The ATMA CENA intake call discusses both pathways honestly. See Ketamine Therapy for PTSD.
59. What if my SAP application is denied? Options include resubmitting with additional documentation, identifying a different prescriber, or pursuing alternative PTSD treatments. Ketamine therapy with broader access is often the realistic alternative.
60. Where can I learn more? The full MDMA cluster:
- Foundation: MDMA-Assisted Therapy in Canada (Hub), What Is MDMA-Assisted Therapy?
- Access: How to Access MDMA-Assisted Therapy in Canada (SAP), Is MDMA Therapy Legal in Canada?
- Cost: MDMA-Assisted Therapy Cost in Canada
- Indications: MDMA-Assisted Therapy for PTSD, MDMA-Assisted Therapy for Veterans
- Modality: What to Expect at an MDMA-Assisted Therapy Session, Side Effects and Safety
- Quebec: MDMA-Assisted Therapy in Quebec
- Comparison: MDMA vs Ketamine for PTSD
Sources
- Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
- Mitchell JM, et al. (2021). MAPP1 Phase 3 in severe PTSD. Nat Med. https://pubmed.ncbi.nlm.nih.gov/33972795/
- Mitchell JM, et al. (2023). MAPP2 Phase 3 in moderate-to-severe PTSD. Nat Med. https://pubmed.ncbi.nlm.nih.gov/37709999/
- Mithoefer MC, et al. (2018). Phase 2 RCT in military veterans, firefighters, police. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29728331/
- Mithoefer MC, et al. (2010). First MAPS-sponsored open-label Phase 2. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/20643699/
- Sessa B, Higbed L, Nutt D (2019). MDMA-AT review. Front Psychiatry. https://pubmed.ncbi.nlm.nih.gov/30916641/
- Bryant J, et al. (2024). Meta-analysis of ketamine for PTSD — comparison context. Eur J Psychotraumatol. https://pmc.ncbi.nlm.nih.gov/articles/PMC10791091/
- TheraPsil: https://therapsil.ca/
- MAPS Canada: https://www.mapscanada.org/
- Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
- FDA Complete Response Letter on MDMA-AT (August 2024): https://www.psychiatrictimes.com/view/fda-releases-complete-response-letter-on-declining-mdma-assisted-therapy-for-ptsd
Related articles in this cluster
All cluster articles are linked above by topic. The hub at MDMA-Assisted Therapy in Canada is the cluster entry point.
Last updated: 2026-05-06